Orlistat Capsules

Orlistat is a long-acting and potent specific gastrointestinal lipase inhibitor. It exerts its therapeutic effect by forming a covalent bond with the active serine site of gastric lipase and pancreatic lipase in the stomach and small intestine to inactivate the enzyme. The inactivated enzyme cannot hydrolyze the fat in the food (mainly triglycerides) into absorbable free fatty acids and monoacylglycerol. Undigested triglycerides cannot be absorbed by the body, thereby reducing calorie intake and controlling weight. The drug does not need to be absorbed through the whole body to exert its efficacy.

The main ingredient of this product and its chemical name are: (S)-2-Formylamino-4-methyl-pentanoic acid (S)-1-[[(2S,3S)-3-hexyl-4-oxo-oxetanyl]methyl]-dodecyl ester.

This product is a hard capsule, and the contents are white or off-white granules.

Combined with a low-calorie diet, it is suitable for long-term treatment of obese and overweight patients, including those who have already developed risk factors associated with obesity. It has the effect of long-term weight control (weight loss, weight maintenance and prevention of rebound). It can reduce the incidence of risk factors associated with obesity and other diseases related to obesity, including hypercholesterolemia and type 2 diabetes.

Adults: Take 1 tablet orally during or within 1 hour after a meal. If you skip a meal or the food does not contain fat, you can skip the dose.

This product mainly causes gastrointestinal adverse reactions, which are related to the pharmacological mechanism of the drug to prevent the absorption of ingested fat. Common adverse reactions are: oily spots, increased gastrointestinal flatulence, urgency to defecate, fatty (oily) stools, steatorrhea, increased frequency of bowel movements and fecal incontinence.

1. Patients who are allergic to orlistat or any of the ingredients in the preparation are contraindicated. 2. Patients with chronic malabsorption syndrome or cholestasis are contraindicated. 3. Patients with organic obesity (such as hypothyroidism) are contraindicated.

Precautions for children: The safety and efficacy of orlistat have been evaluated in obese adolescent patients aged 12 to 16 years old, and no dosage adjustment is required for patients in this age group taking orlistat. Safety and efficacy studies of orlistat for children under 12 years old have not been conducted. Precautions for pregnancy and lactation: No embryotoxicity or embryonic malformations associated with orlistat were observed in animal reproductive toxicity studies. However, animal reproductive toxicity studies cannot always accurately predict human responses, and in the absence of clinical data, it is not recommended that women take this product when pregnant. It is not clear whether orlistat is secreted in human milk, so breastfeeding women should not take this product. Precautions for the elderly: There is a lack of sufficient clinical research data to prove whether the use of orlistat in people aged 65 and above is different from that in younger patients.

1. This product can reduce the absorption of vitamins A, D and E. This product can be supplemented at the same time. If you are taking preparations containing vitamins A, D and E (such as some compound vitamin preparations), you should take it 2 hours after taking this product or before going to bed. 2. Patients with type 2 diabetes may need to reduce the dose of oral hypoglycemic drugs (such as sulfonylureas). 3. When this product is used in combination with cyclosporine, it may cause a decrease in the latter's plasma concentration. 4. When this product is used in combination with amiodarone, it may lead to reduced absorption of the latter and reduce its efficacy. 5. If you are taking other medicines, please consult a physician or pharmacist before using this product.

Sealed, stored in a cool and dry place (not exceeding 20°C)

0.12 g

24 months

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

• Founded in:

  1992-12-31

• Address:

  No. 866, Moganshan Road, Gongshu District, Hangzhou City, Zhejiang Province

• Tax NO.:

  91330100609120774J

• Registered Funds:

  872.30813 million yuan

• Website:

  Log in to view

• Email:

  Log in to view